Lindsey Kennedy, Vik Meadows, Amelia Sybenga, Jennifer Demieville, Lixian Chen, Laura Hargrove, Burcin Ekser, Wasim Dar, Ludovica Ceci, Debjyoti Kundu, Konstantina Kyritsi, Linh Pham, Tianhao Zhou, Shannon Glaser, Fanyin Meng, Gianfranco Alpini, Heather Francis – 11 January 2021
Coagulation disorders in patients with cirrhosis present challenging situations for clinical providers. This one hour webinar will summarize the knowledge behind coagulation disorders in patients with cirrhosis, including the mixed and thrombosis prone model, limitations in current tests of hemostasis, and the dangers of excessive transfusion.
Hima Veeramachaneni, Ram M. Subramanian – 10 January 2021
Jasmohan S. Bajaj, Guadalupe Garcia‐Tsao, Florence Wong, Scott W. Biggins, Patrick S. Kamath, Sara McGeorge, Michael Chew, Meredith Pearson, Jawaid Shaw, Anita Kalluri, Andrew Fagan, Amy Olofson, Maryam Moini, Randolph Rosa Rodriguez, K. Rajender Reddy – 10 January 2021
iangfa Li, Xiaofei Ye, Songqing He – 10 January 2021
John E. Eaton, Shannon P. Sheedy, Gregory J. Gores, Sudhakar K. Venkatesh – 10 January 2021
Kshitij Thakur, Jessica McFarlin – 9 January 2021
Allyson J. Merrell, Tao Peng, Jinyang Li, Kathryn Sun, Bin Li, Takeshi Katsuda, Markus Grompe, Kai Tan, Ben Z. Stanger – 9 January 2021
Laurent Spahr, Nicolas Lanthier, Mathieu Tihy, Jean‐Louis Frossard, Laura Rubbia‐Brandt, Nicolas Goossens – 8 January 2021 – Acute alcoholic microvesicular steatosis (MIC) may complicate heavy alcohol intake and present as alcoholic hepatitis (AH) syndrome. However, detailed clinical, biological, and histologic data associated with MIC are scarce. We compared the clinical presentation, histologic features, and hepatic transcriptomic of patients presenting with AH due to either MIC or severe alcoholic steatohepatitis (ASH).
Paolo Caraceni, Victor Vargas, Elsa Solà, Carlo Alessandria, Koos Wit, Jonel Trebicka, Paolo Angeli, Rajeshwar P. Mookerjee, François Durand, Elisa Pose, Aleksander Krag, Jasmohan S. Bajaj, Ulrich Beuers, Pere Ginès, for the Liverhope Consortium – 8 January 2021 – Rifaximin is an oral nonsystemic antibiotic with minimal gastrointestinal absorption and broad‐spectrum antibacterial activity covering both gram‐positive and gram‐negative organisms.